House Representatives Paul Tonko (D-N.Y.) and Vern Buchanan (R-Fla.) are leading the charge in addressing one of the most pressing healthcare issues of our time – Alzheimer’s disease. At The Hill’s “Getting a Diagnosis ASAP: Progress in Early Alzheimer’s Detection” event on Thursday, the two congressmen emphasized the urgency of proactively addressing this devastating disease.
Tonko and Buchanan are co-sponsors of the Alzheimer’s Screening and Prevention (ASAP) Act, which aims to improve early detection and diagnosis of Alzheimer’s disease. The act would provide Medicare coverage for comprehensive Alzheimer’s screenings, as well as establish a national education campaign to raise awareness about the importance of early detection.
During the event, both representatives stressed that Alzheimer’s disease is not only a personal tragedy for the millions of Americans affected by it, but also a significant financial burden on our healthcare system. Tonko stated, “This is too expensive of an issue for Congress to ignore.” He pointed out that the cost of caring for individuals with Alzheimer’s and other dementias is estimated to reach $1.1 trillion by 2050.
Buchanan echoed this sentiment, saying, “We can’t afford not to address this issue.” He emphasized the need for early detection and intervention, as it can significantly reduce healthcare costs and improve the quality of life for those living with Alzheimer’s.
The urgency of addressing Alzheimer’s disease was further highlighted by the fact that it is the sixth leading cause of death in the United States and the only one in the top 10 without a cure or effective treatment. As the population ages, the number of individuals living with Alzheimer’s is expected to triple by 2050.
The ASAP Act has received bipartisan support, with 77 co-sponsors in the House of Representatives and 17 in the Senate. Tonko and Buchanan are hopeful that the act will be passed and signed into law, as it has the potential to make a significant impact in the fight against Alzheimer’s.
In addition to discussing the ASAP Act, the event also featured a panel of experts who shared the latest advancements in early detection and diagnosis of Alzheimer’s disease. They emphasized the importance of research and innovation in finding a cure for this devastating disease.
The event also highlighted the need for increased funding for Alzheimer’s research. Currently, the National Institutes of Health (NIH) spends only 0.3% of its budget on Alzheimer’s research, despite the fact that it is one of the leading causes of death in the country. Tonko and Buchanan are committed to advocating for increased funding for Alzheimer’s research and ensuring that it remains a top priority for the NIH.
The Alzheimer’s Association, which co-hosted the event, praised Tonko and Buchanan for their leadership in addressing this critical issue. “We are grateful for the support of Representatives Tonko and Buchanan in the fight against Alzheimer’s,” said Robert Egge, Chief Public Policy Officer of the Alzheimer’s Association. “Their bipartisan efforts to improve early detection and diagnosis are crucial in our mission to end this disease.”
In conclusion, Representatives Tonko and Buchanan are leading the way in addressing Alzheimer’s disease and its devastating impact on individuals, families, and our healthcare system. The ASAP Act, along with increased funding for research, has the potential to make a significant difference in the fight against this disease. As Tonko stated, “We have to act now, because the cost of inaction is too high.” Let us hope that Congress heeds this call and takes proactive steps to address Alzheimer’s disease.
